We are delighted to welcome Naomi Clout to the team as Senior Regulatory and Medical Writer, after working with the company on a consultancy basis for a number of years.
Having been a regulatory medical writer since 2005, Naomi has experience of writing and editing a wide range of regulatory documents for a variety of pharmaceutical companies. After completing a post-doctoral research position at Imperial College London, she began her career at Quantum Medical Communications where she worked as a trainee regulatory medical writer. Naomi later joined Pfizer to manage all aspects of CSR writing.
Following this, she took the opportunity to join a newly created medical writing group, with colleagues from Pfizer, within an established biostatistics CRO (now Quanticate) that went on to become the preferred provider for some of the top ten pharmaceutical companies. At Quanticate, she was a senior editorial associate specialising in QC and the peer review of regulatory documents.
In her role at Boyds, Naomi will prepare high quality regulatory medical writing and documentation to support clients’ drug development activities.
Of joining Boyds, Naomi said: “Boyds is a company with a strong reputation in the industry and is well known for its leading experts and innovative thinkers. I am excited to be working alongside colleagues who will be taking academic discoveries right through product development to marketing authorisation, and the future impact these products may have on patients.
“The collaborative nature of Boyds’ work greatly appealed to me, with each team member’s skills and specialisms utilised to achieve the best possible end result. Boyds also has a real openness to innovation and change which I believe is vital to success in drug development.”
Dr Karen Mullen, Chief Medical Officer and Head of Clinical and Medical Affairs at Boyds, added: “We are delighted to welcome Naomi to the team as we continue to see an increase in demand for our medical writing services. Naomi brings a wealth of experience and expertise to the company, and we have no doubt that she will be an immediate asset to the Clinical and Medical Affairs department and our clients.”
